Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-2828 in Participants With Renal Impairment
NCT07348237Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-2828 (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity at 192 hours, Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration at 192 hours and 7 more. Started Mar 2026; status: completed.
02
Drugs
MK-2828
Beyond the preview
Go deeper on NCT07348237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348237.